Cosmo Pharmaceuticals: AI-Driven Growth with Andrea Cherubini at the Helm

Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) has appointed Andrea Cherubini as its new Chief AI Officer, effective immediately. This strategic move reflects the company's commitment to integrating artificial intelligence (AI) as a core pillar of its future growth and innovation roadmap. Cherubini, who previously served as Senior Vice President - Science, AI, and Data, has been instrumental in developing GI Genius™, the world's first AI-powered polyp detection system in gastroenterology.

In his new role, Cherubini will spearhead the expansion of AI beyond endoscopy, embedding it across Cosmo's entire portfolio to accelerate innovation, enhance efficiencies, and unlock new value for both patients and shareholders. This includes advancing AI applications in drug development, particularly for Bile Acid Diarrhea (BAD), to drive precision medicine and predictive analytics in GI disorders. Additionally, Cherubini will leverage AI to optimize clinical trial design, patient selection, and personalized treatment pathways for Breezula® and other dermatological innovations. Furthermore, he will expand AI's role in R&D, regulatory strategies, and digital health applications, reinforcing Cosmo's position as a leader in AI-driven healthcare solutions.

Giovanni Di Napoli, CEO of Cosmo, commented on the appointment: "AI is no longer simply an enabler - it is a core pillar of Cosmo's growth strategy. Andrea has already demonstrated his ability to bring AI-powered innovations to market with GI Genius™, and now, as Chief AI Officer, he will lead our AI expansion across the entire organization. We have the expertise, the infrastructure, and the vision to take AI beyond endoscopy and into new frontiers, creating significant value for both patients and shareholders."

Andrea Cherubini, Chief AI Officer, added: "I am honoured to take on this new role at such an exciting time for Cosmo. AI is transforming healthcare, and we are just scratching the surface of its potential. By embedding AI into drug development, diagnostics, and personalized medicine, we can drive real impact. I look forward to working with our talented teams to bring AI-driven solutions to more areas of our portfolio and deliver meaningful advancements in patient care."



Cosmo Pharmaceuticals' AI-driven innovations in the gastroenterology pipeline, focusing on Bile Acid Diarrhea (BAD), are expected to bring significant benefits to patients and shareholders. By leveraging AI for more accurate diagnostics, personalized treatment pathways, predictive analytics, accelerated drug discovery, and enhanced regulatory strategies, Cosmo can differentiate itself from competitors, improve patient outcomes, and strengthen its market position.

In conclusion, Cosmo Pharmaceuticals' appointment of Andrea Cherubini as Chief AI Officer signals a strategic commitment to AI-driven growth and innovation. With Cherubini at the helm, Cosmo is well-positioned to capitalize on the transformative potential of AI in healthcare, driving real impact and delivering meaningful advancements in patient care.